Opinion
Video
Use of Targeted Agents in Generalized Myasthenia Gravis
Author(s):
Key Takeaways
- FcRn and complement inhibitors are used in gMG patients unresponsive to traditional therapies, offering targeted treatment options.
- Long-term management of gMG with these inhibitors requires careful integration into treatment plans for refractory cases.
Panelists discuss how they select patients for FcRn and complement inhibitor therapies, integrate these treatments into long-term management plans, monitor patients on these therapies, and approach treatment for those with inadequate disease control on traditional or targeted therapies for generalized myasthenia gravis.
Video content above is prompted by the following:
- In which patients and when do you typically use FcRn inhibitors and complement inhibitors?
- Where do FcRn inhibitors fit in the long-term management of gMG?
- How do you monitor patients with gMG, especially those receiving FcRn or complement inhibitor therapies?
- How do you manage gMG in patients who have inadequate disease control with traditional treatments and those currently on targeted therapies?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Videos
Related Content
